Uncategorized
Apellis to acquire Potentia Pharmaceuticals
Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals, according to a press release.Through the agreement, Apellis obtained the necessary intellectual property rights to develop a complement inhibitor drug compound (APL-2) for the treatment of dry age-related macular degeneration.